GEN Exclusives

More »

GEN News Highlights

More »
Nov 14, 2008

Valeant Pharmaceuticals Acquires DermaTech for $12.6M

  • Valeant Pharmaceuticals acquired DermaTech for approximately AU$19 million ($12.6 million).

    Earlier this year, under the direction of a new CEO, Valeant revised its business strategy to, among other things, build on its strengths in neurology and dermatology.  DermaTech specializes in the development, production, and distribution of products to address common dermatological conditions; its current annualized net sales total approximately $6.9 million.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?